The cheapest path to tirzepatide depends on your insurance status — and honestly, several options can cost less than a compounded prescription, depending on your situation.
If your insurance covers Zepbound or Mounjaro, a manufacturer savings card is usually the least expensive route. If you're uninsured or your plan excludes weight-loss coverage, self-pay brand vials and compounded tirzepatide become the more realistic comparison — and pricing varies more between compounded providers than people expect.
Tirzepatide's brand list price — commonly over $1,000/month for Zepbound or Mounjaro without insurance — puts it out of reach for a lot of patients paying entirely out of pocket. The good news is that "brand list price" is rarely what anyone actually ends up paying. Here's how the realistic options stack up.
Option 1: Insurance Coverage + Manufacturer Savings Card
If your insurance plan covers Zepbound or Mounjaro for weight management, Eli Lilly's savings card can bring your out-of-pocket cost down substantially — sometimes to as little as $25/month for commercially insured patients whose plan already covers the medication. This is the cheapest legitimate path when it applies, but it only applies if your specific plan covers weight-loss GLP-1 treatment, which isn't universal. Roughly 49% of large employers now cover GLP-1s for weight management as of 2025, up from 44% the year before — check your specific formulary and prior authorization requirements rather than assuming coverage either way.
Option 2: Manufacturer Self-Pay (LillyDirect)
For patients without insurance coverage, Eli Lilly's direct-to-consumer self-pay program offers single-dose vials of Zepbound at a lower price than traditional retail pharmacy cash price, though still meaningfully more than compounded alternatives. This route gets you the FDA-approved branded product without going through insurance, at a middle-ground price point.
Manufacturer Patient Assistance Programs
Beyond the standard savings card, Eli Lilly maintains a separate patient assistance program (PAP) for uninsured or underinsured patients who meet specific income eligibility thresholds, which can provide tirzepatide free or at a steep discount for qualifying applicants. This program is distinct from — and has different eligibility rules than — the commercial savings card, and it's worth checking directly with the manufacturer or your provider whether you might qualify, particularly if your household income falls within a lower range relative to the federal poverty level. Applications typically require income documentation and can take several weeks to process, so this isn't usually a fast option if you need treatment immediately, but it's worth pursuing in parallel with a faster short-term option if you expect to need tirzepatide long-term and might reasonably qualify based on your household situation. If you're currently paying cash and your income has recently changed — a job loss, reduced hours, or a new dependent — it's worth checking your eligibility even if you assumed you wouldn't qualify previously, since income thresholds and household size calculations can shift your eligibility status from one year to the next.
Comparing Total First-Year Cost Across All Paths
Putting the options side by side over a full year makes the tradeoffs clearer than any single monthly figure. Insurance plus a qualifying savings card: roughly $300/year in the best-case scenario. Manufacturer self-pay vials at a stable mid-range dose: roughly $4,200-$5,400/year depending on which dose you settle at long-term. Flat-rate compounded tirzepatide at $297/month: $3,564/year, with no variation by dose. A tiered compounded provider advertising a lower starting price but charging more at maintenance dose: potentially similar to or higher than the flat-rate option once you account for the higher-tier pricing you'll likely reach. Running these numbers for your own specific situation, rather than comparing headline monthly prices in isolation, is the only way to identify which path is genuinely cheapest for you over the full course of treatment you're likely to need.
Option 3: Compounded Tirzepatide Through Licensed Telehealth
Compounded tirzepatide, prepared per individual prescription by state-licensed 503A pharmacies, contains the same active pharmaceutical ingredient as Zepbound and Mounjaro at a lower price point than either brand option. This is where price comparison gets genuinely confusing, because published rates across the compounded telehealth market vary widely — from roughly $99-125/month at some providers up to $300+ at others, and starter-dose pricing is sometimes advertised while therapeutic maintenance-dose pricing (what most patients actually pay long-term) runs higher. It's worth comparing the maintenance-dose price, not just the lowest advertised number, and confirming the pharmacy's state licensing before choosing based on price alone.
Luma Health's compounded semaglutide is $197/month and tirzepatide is $297/month, flat across dose levels, with no separate consultation fee layered on top. That's not the lowest price in the compounded market — some other telehealth providers advertise lower monthly rates for tirzepatide specifically. What that flat structure does offer is price certainty: your monthly cost doesn't increase as your dose increases, which matters since therapeutic maintenance doses are often priced higher than starter doses at providers using tiered pricing.
If lowest possible monthly cost is your only priority, it's worth shopping the compounded market directly, since some providers do advertise lower rates than Luma Health's $297/month tirzepatide. What we'd ask you to weigh alongside price: pharmacy licensing transparency, whether the price holds steady as your dose increases, and how easy it is to actually reach a provider with questions.
If Insurance Initially Denies Coverage
A first-attempt insurance denial for tirzepatide isn't necessarily the end of the road, and it's worth pursuing an appeal before assuming you're stuck paying cash. Common, addressable denial reasons include missing documentation of your BMI or weight-related comorbidities, a step-therapy requirement to try other treatments first, or a formulary tier issue that a clinical exception letter can sometimes resolve. A well-documented appeal — addressing the specific reason cited in your denial letter, with a letter of medical necessity from your provider — has a meaningful success rate when the underlying issue is a documentation gap rather than a blanket plan exclusion, and it's generally worth the extra effort before assuming cash-pay is your only remaining option.
If your denial is instead based on a hard plan-level exclusion of weight-loss medications as a category, an appeal won't change that outcome, since it's a plan design decision rather than a case-specific judgment. In that situation, your realistic options shift toward the cash-pay paths described above, or raising the exclusion with your employer's HR department if it's an employer-sponsored plan, since some employers reconsider these exclusions at their next annual renewal.
Calculating Your Real Monthly Cost at Your Actual Dose
One of the more common mistakes when comparing "cheapest" options is anchoring on a provider's lowest advertised starting-dose price, then discovering the price rises considerably once you reach a therapeutic maintenance dose. Before choosing based on price, ask any provider directly: what will I pay per month once I'm at my likely maintenance dose (commonly 10mg or 15mg for tirzepatide), not just at the 2.5mg starting dose most introductory pricing reflects. Some providers use genuinely flat pricing across all doses; others use a tiered structure where the advertised low price applies only to the lowest strength offered. This single question can meaningfully change which option is actually cheapest for your specific treatment course over time.
What to Verify Before Choosing Based on Price Alone
Unusually low advertised pricing is a signal to look closer, not necessarily a red flag on its own. Before choosing any provider based primarily on cost, confirm: the compounding pharmacy's state board license (verifiable directly through that state's board of pharmacy website), whether the price you see is the starter dose or the maintenance dose you'll actually be on long-term, and whether a real medical evaluation happens before a prescription is issued. A site offering tirzepatide without any clinical evaluation is a red flag regardless of price, and this remains true no matter how compelling the advertised savings appear at first glance.
Which Path Fits You
- Have commercial insurance and haven't confirmed your GLP-1 coverage
- Are willing to navigate prior authorization requirements
- Want the FDA-approved branded product specifically
- Don't have insurance coverage for weight-loss GLP-1s
- Want price certainty as your dose increases over time
- Value ongoing provider access as part of the price, not a separate fee
One flat price,
real medical evaluation
Compounded tirzepatide at $297/month, flat across dose levels, prepared by a Texas-licensed 503A pharmacy — with an actual provider reviewing your case first.
Get Started → Or start your free health assessmentFrequently Asked Questions
If your insurance covers Zepbound or Mounjaro for weight management, a manufacturer savings card is typically the least expensive route, sometimes as low as $25/month. Without that coverage, self-pay brand vials or compounded tirzepatide become the realistic comparison, and pricing varies meaningfully between compounded providers.
Coverage varies significantly by plan. Roughly 49% of large employers now cover GLP-1s for weight management as of 2025, but coverage isn't universal and often requires prior authorization. Check your specific formulary directly.
Compounded tirzepatide contains the same active pharmaceutical ingredient, but it isn't itself an FDA-approved finished drug product the way Zepbound and Mounjaro are. Quality depends heavily on the compounding pharmacy's licensing and process, which is why verifying the pharmacy matters.
Some providers advertise low starter-dose pricing that increases substantially at therapeutic maintenance doses, while others use a flat rate across all dose levels. Comparing the maintenance-dose price, not just the advertised starting rate, gives a more accurate picture of what you'll actually pay long-term.
Not necessarily the cheapest advertised rate in the compounded market — some providers list lower monthly prices. Luma Health's $297/month flat rate offers price certainty across dose levels and includes ongoing provider access, which is the trade-off worth weighing against the lowest sticker price elsewhere.
Confirm the compounding pharmacy's state board license, whether the advertised price is the starter or maintenance dose, and that a real medical evaluation happens before any prescription is issued. Skip any provider that prescribes without a clinical evaluation, regardless of price.
Yes, if the denial was based on missing documentation, step therapy, or a formulary issue. A well-documented appeal addressing the specific denial reason, including a letter of medical necessity from your provider, has a meaningful chance of success. A blanket plan-level exclusion of weight-loss medications, however, won't be resolved by an appeal since it's a plan design decision rather than a case-specific judgment.
Some providers advertise their lowest starting-dose price prominently, while pricing tiers upward at higher therapeutic doses. Always ask what you'll pay at your expected maintenance dose, not just the starting price, before comparing options.
An appeal won't change a blanket exclusion, since it's a plan design decision. Raising it with your HR department is worth trying, since some employers reconsider these exclusions at their next annual renewal.
References
- U.S. Food and Drug Administration. Prescribing Information for Zepbound (tirzepatide). FDA.gov. 2025. FDA.gov
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
- Mercer. National Survey of Employer-Sponsored Health Plans, 2025: GLP-1 coverage findings. Mercer.com. 2025. Mercer.com
- U.S. Food and Drug Administration. Human Drug Compounding and the FD&C Act. FDA.gov. FDA.gov
- U.S. Food and Drug Administration. BeSafeRx: Your Source for Online Pharmacy Information. FDA.gov. 2026. FDA.gov